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Background: Heart failure is known to be associated with increased adverse clinical
outcomes in coronary artery diseases. The impact of percutaneous coronary inter-
vention (PCI) for chronic total occlusion (CTO) in patients (pts) with new onset heart
failure is not clear. We compared the 12-month clinical outcomes of pts treated by PCI
with optimal medical therapy (OMT) for CTO lesions in pts with new onset heart
failure.
Methods: A total of 458 consecutive CTO pts newly diagnosed with heart failure or
showing symptoms of heart failure (NYHA class 2 or CCS class 2) were divided
into 2 groups; one group underwent PCI (PCI group; n¼246) and the other group was
treated with OMT (OMT group; n¼212). Major clinical outcomes were compared
between the two groups up to 12 months.
Results: At baseline, the OMT group had a higher prevalence of elderly, cerebro-
vascular accidents, de novo lesion, left main disease, multivessel disease, multivessel
CTO, RCA-CTO, and abundant collaterals (grade 2), whereas the PCI group had a
higher prevalence of male gender, prior MI, prior PTCA and LAD-CTO lesions.
Clinical outcomes at 12 months were similar between the 2 groups except lower
mortality in the PCI group (Table). After baseline adjustment by multivariate analysis,
however, there was no difference between the 2 groups.
Conclusion: In our study, mechanical revascularization by PCI for CTO lesions in pts
with new onset heart failure as compared with OMT seems to have no beneﬁt in
reducing 12-month mortality. Long-term follow up with a larger study population will







Comparison in Cardiac Remodeling Between Surgical Treatment and Device
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Background: Atrial septal defect (ASD) is the 2nd most common congenital heart
anomaly in adults. As treatment options, there are operative ASD closure (Surgery)
and percutaneous device closure (Device). The aim of this study was to elucidate the
cardiac remodeling after ASD closure and to compare the effects of Surgery and
Device in similar ASD size.
Methods: Among patients who underwent ASD closure in Catholic medical school,
St. Vincent’s Hospital from January 2004 to December 2012, 28 patients were
enrolled. Transthoracic echocardiography (TTE) was performed before and after
correction of the ASD in both Surgery and Device groups.
Results: Although therewere signiﬁcant differences in age andASD size in both groups,
after closing ASD, LV dimension increased in both groups, on the other hand, decrease
in right atrium volume (RAVol) and maximum regurgitation velocity of tricuspid valve
(TR Vmax) was noted. Aortic diameter and LV ejection fraction increased in Surgery
group. Further subgroup analysiswithASD size of 13 to 24mmwas analyzed to compare
differences in cardiac remodeling between the two groups. There were coherent results
of increase of LV dimension and reduction of TR Vmax and RAVol in both subgroups.
However, RAVol reduction was more remarkable in Surgery than Device subgroup.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/POSTConclusion: Although there was difference in baseline parameters between two
groups, which may have affected the choice of treatment option, the parameters
measured by TTE showed signiﬁcant change in structural cardiac remodeling. By
subgroup analysis regarding to ASD size, showed consistent improvements in cardiac
geometry without signiﬁcant difference between the groups. In conclusion, in selected
cases of ASD, it is reasonable to treat percutaneously considering complication
occurrence, post-procedural recovery, and hospital stay.Drug-eluting Stents
(TCTAP A-166 to TCTAP A-171)
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Background: A novel dual therapy stent (DTS) may improve clinical outcome due to
a combination of sirolimus drug elution and endothelial progenitor cell technology for
reduced restenosis and accelerated endothelisation. However clinical data remains
limited on the use of this novel technology. We aim to report on the use of a novel
DTS device in our centre.
Methods: All patients who underwent PCI with the ComboR DTS in our centre were
enrolled. All patients underwent diagnostic angiograms and PCI according to guide-
line recommended indications and techniques. Baseline clinical and angiographic
characteristics were collected. Clinical outcomes for MACE at 6 and 12 months were
studied.
Results: Fifty three patients (83% male) of mean age 61.42 +/- 11.63 years were
studied. 15.1% (n¼ 8), 24.5% (n¼ 13) and 60.4% (n¼ 32) were admitted for STEMI,
ACS and Stable angina respectively. The prevalence of hypertension, hyperlipidaemia
and diabetes mellitus were 88.7% (n¼47), 75.5% (n¼ 40) and 50.9% (n¼ 27)
respectively. 12.7% (n¼ 7) had left main disease and 41.8% (n¼ 23) had triple vessel
disease. 69 ComboR DTS with a mean diameter of 3.06 +/- 0.35 mm and a mean
length of 22.07 +/- 5.55 mm were implanted. 50.7% (n¼ 35), 11.6% (n¼ 8) and
39.0% (n¼ 20) were implanted in the LAD, LCx and RCA respectively. 4.3% (n¼ 3)
were deployed in the left main artery and in bypass grafts respectively. There were
10.1% (n¼9), 69.6% (n¼48) and 20.3% (n¼ 14) ACC/ AHA angiographic type A, B
and C lesions. 6 (8.7%) and 7 (10.1%) were CTO and bifurcation lesions respectively.
Angiographic success rate was 100%. There were no cases of stent thrombosis or
inhospital mortality.
Conclusion: The use of ComboR DTS was associated with excellent angiographic and
short term clinical outcome in this study. We plan to report on 6 month clinical
outcomes at the time of presentation.TCTAP A-167
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Background: Aim of the study was to evaluate the primary procedural success of
percutaneous coronary intervention (PCI) of de-novo coronary artery lesion by using
BVS Absorb stents eluting with Everolimus.
Methods: Total 16 patients were enrolled in this very preliminary study of BVS
absorb. Among them, Male: 11 and Female: 5. Total 20 stents were deployed. Mean
age were for Male: 56 yrs, for Female: 60 yrs. Associated CAD risk factors were
Dyslipidemia, High Blood pressure, Diabetes Mellitus, Positive FH for CAD and
Smoking (all male).
Results: Among the study group; 13 (81%) were Dyslipidemic, 10(62.5%) were
hypertensive; 6 (37.5%) patients were Diabetic, FH 3(18.75%), and 2(18%) were
all male smoker. Female patients were more obese (BMI M 25: F 27) and
developed CAD in advance age. A common stented territory was for LAD: 6
(37.5%), LCX 5 (25%), RCA 6(37.5%). One patient had both LCX and LAD
stenting. Total 3 patients had double/overlapping stent in RCA lesion. Territory
wise distributions of BVS Absorb stent were for LAD 6(30%), RCA 9 (45%), and








19th CardioVascular Summit: TCTAP 2014Conclusion: BVS absorb Everolimus eluting vascular scaffold showed favorable
clinical outcome without any major cardiac events (acute or late stent thrombosis, MI
or death) over a period of 9 month. Thus, BVS absorb would be favorable alternative
to other available drug eluting metallic stents.
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Background: With increasing complex PCI’s, long stents have been increasingly
used. However the long-term clinical outcomes of these stents have not been well
studied.
Methods: A retrospective analysis of 586 consecutive patients who underwent PCI
using paclitaxel DES (Taxus Liberté) during the period December 2005 to August
2007 was done. 90.1% were followed up for a median duration of 60 months (12- 86
months). Long stents were deﬁned as 28mm (group A)-178 patients (33.7%) were
compared to relative short stents 24mm (group B)-350 patients (66.3%).
Results: The study population was a high risk group with 43.3% diabetics in group A
and 46.3% in group B (p-0.524). other baseline characteristics were also well matched
except for inducible ischemia on treadmill which were more in group A 42.7% vs
group B 31.9% (p-0.012), patients in group A requiried more than one stent 50.6% vs
group B 37.7%(p –0.004) and patients in group A had more RCA interventions than
group B – 38.2% vs 25.7% (p-0.002). Mean no of stents implanted per patient was 1.5.
MACCE at hospital discharge was 0% in group A vs. 0.7% in group B (p – 0.557), at
1 year was 4.4% vs 4.3% (p-0.984), at 5 years was 12.8% vs 13.6% (p-0.871).TLR at
discharge was 0% in group A and 0.2% in group B (p-1.0), at 1 year was 3.1% vs
1.1% (p-0.138), at 5 years was signiﬁcantly higher in group A 4.9% vs 1.6% (p-
0.025).There is no difference in stent thrombosis at discharge 0% in group A vs.0.2%
group B (p-0.681), at 1 year 0.6% vs.1.6% (p-0.681), at 5 years was 0.6% vs 2.1% (p-
0.290). At 5 years, Deﬁnite ST was 0.6% in group A vs 0.3% group B (p-0.513),
Probable ST 0% vs 0.3% (p-1.0), Possible ST 0.6% vs 2.7% (p- 0.186). There was no
in hospital mortality in either groups, mortality at 1 year was 0% in group A vs 1.6%
in group B (p-0.185), at 5 years 2.5% vs 5.3% (p-0.175). The overall event-free
survival at 5 years was comparable in both the groups (87.2%vs.86.4%).
Conclusion: Clinical outcomes of long paclitaxel drug eluting stents ( 28 mm) were
comparable to relatively short stents ( 24mm) at 5 years.
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Background: The aim of this study is to compare clinical outcomes between 1st
generation sirolimus eluting stent and 2nd generation everolimus eluting stent in pa-
tients with diffuse long lesions for 2 years.
Methods: A total 381 Patients with diffuse long lesion treated with  50 mm stent
segment in de novo lesions from Jan 2006 to Aug 2011 were enrolled. The patients
were divided into two groups as sirolimus eluting stent (SES, n¼265) group and
everolimus eluting stent (EES, n¼116) group. Study end-points were major adverse
cardiac events (MACE) including all death, myocardial infarction (MI), and ischemic
driven target vessel revascularization (Id-TVR).
Results: Baseline characteristics were similar. Stent length was 61.711.0 in SES and
62.813.7 in EES (p¼0.593). For 2 years clinical follow-up, the rate of cumulative
MACE was 10.7% in SES and 7.4% in EES (p¼0.346). The rate of all death was
observed 5.7% in SES and 6.3% in EES group (p¼0.840). The rate of MI was
observed 2.3% in SES and 5.3% in EES (p¼0.153). The rate of Id-TVR was observed
7.7% in SES and 6.3% in EES (p¼0.666).
Conclusion: The clinical outcomes between SES and EES in patients with diffuse
long lesions were not different for 2 years. Further longer term follow-up and larger
population study will be needed for better evaluation.
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Background: Previous studies have demonstrated that patients with small coronary
artery lesions (SCAL) are at increased risk for late cardiac events after percutaneous
coronary intervention (PCI). It remains uncertain whether second-generation drug-
eluting stents have an advantage ﬁrst-generation drug-eluting stents (DES) in patients
with SCAL. This study aimed to evaluate the long-term efﬁcacy of everolimus-eluting
stent(EES) and sirolimus-eluting stents(SES) on SCAL.
Methods: Consecutive 353 patients with 400 SCAL, who were treated with EES (153
patients, 180 lesions) and SES (203 patients, 220 lesions) were enrolled. SCAL was
deﬁned the lesions with reference vessel diameter(RVD) <2.5 mm. Within ten months
angiographic follow-up results and 2-year clinical follow-up outcomes were compared
between EES and SES groups.
Results: The prevalence of diabetes was higher and the stent length was longer
(22.97.0 vs. 20.17.0, p<0.05) in EES group than in SES group. Initial success rate
was similar in both groups. There was no difference in 2-year %binary restenosis,
TLR (1.7vs. 4.7%), and MACE (3.3%vs 6.4%) rates between 2 groups. This similar
major adverse cardiovascular events rate remained after adjustment. However, the rate
of stent thrombosis was 0% in the EES group and 1.8% in the SES group (p ¼ 0.12).
Conclusion: EES demonstrated comparable clinical outcomes to those of SES in
SCAL. The absence of stent thrombosis among patients treated with EESs suggests a
good safety proﬁle for this second-generation drug-eluting stent, which should be
carefully studied in a larger series of patients with SCAL.
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Sirolimus Eluting Stent Shows Better Patency with Reduced ISR Development
for a Period of 3.4 yrs in Bangladeshi Stent Era: Our Experiences in Apollo
Hospitals Dhaka
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Background: Nature of Coronary artery disease (CAD) in Bangladeshi population is
diffuse with small caliber arteries. Now a days, these are treated, by PCI with stent
deployment. However, long term data on In-stent re-stenosis (ISR) in these patients
are not yet available. Therefore, the aim of our present study was to assess long-term
outcome of stent patency or the development of ISR of varieties stent in single vessel
territory.
Methods: Patients were selected retrospectively, who underwent coronary angiogram
at our hospital for further evaluation of their previous PTCA in the 3->36 months
preceding the study for the quantifying period of 2006-2012. Total 577 patients (male:
474, Female: 103) were included in this study. Average age was Male: 56; Female: 59.
Average study period was 3.4.
Results: Our result shows that among the total studied population 82.1% (474) were
male and 17.9% (103) were female. Female were more obese than male BMI (27 vs
26). Total 864 stent were deployed in 785 vessels. Common stented territories were in
LAD 366 (46.6%), RCA 236 (30.1%) and LCX 183 (23.3%). Stent used were BMS
105(30.8%), DES 236 (69.2). Territory wise total number of deployed stent in LAD
396 (45.8%), RCA 272 (31.5%) and LCX 196 (22.7%. Single artery stent were done
in 442 (76.6%), double artery stent in 128 (22.2%) and Triple artery in 7 (1.2%)
patient. Total 94 (16.3%) patient had double/multiple stent in a single vessel territory.
Re-look Coronary Angiogram (CAG) revealed that the patency of stents in BMS 210
(56.5%) and DES 308 (73.5%) treated vessel. Signiﬁcant ISR (ISR>60%) developed
in BMS 97(26.1%) and DES 74 (17.6%). Among the different DES; patency in
Sirolimus 75.2% (157), Everolimus 70.7% (51), Paclitaxel 65.4% (71) and in Bio-
limus-A9 88.2% (15). Among the different DES the development of signiﬁcant ISR
were in Paclitaxel 20.4% (22), Sirolimus 18.6%(39), Everolimus 15.7%(11). Although
the other Biolimus
Conclusion: In our present prospective cohort, Sirolimus Eluting Stent shows better
patency with reduced ISR for an average period of 3.4 years.April 22–25, 2014 j TCTAP Abstracts/POSTER/Drug-eluting Stents
